Lymphoma Clinical Trials in Jinan, Shandong
29 recruitingJinan, Shandong, China
Showing 1–20 of 29 trials
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled195 locationsNCT06136559
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled265 locationsNCT06191744
Recruiting
Phase 2
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China30 enrolled14 locationsNCT07441993
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502
Recruiting
Phase 2
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals155 enrolled17 locationsNCT06539182
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.68 enrolled29 locationsNCT07082686
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 2Phase 3
Newly-diagnosed Pediatric T-cell ALL Protocol
Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute LymphoblasticT Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China610 enrolled27 locationsNCT06855810
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936
Recruiting
Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Advanced Solid TumorAdvanced Lymphoma
CStone Pharmaceuticals480 enrolled38 locationsNCT05279300
Recruiting
Phase 2
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Multiple MyelomaLymphoma
Institute of Hematology & Blood Diseases Hospital, China120 enrolled7 locationsNCT05294055
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.55 enrolled24 locationsNCT06854445
Recruiting
Phase 1Phase 2
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.415 enrolled4 locationsNCT06021678